133 related articles for article (PubMed ID: 33401634)
1. Screening of an FDA-Approved Library for Novel Drugs against
Gur D; Chitlaru T; Mamroud E; Zauberman A
Antibiotics (Basel); 2021 Jan; 10(1):. PubMed ID: 33401634
[No Abstract] [Full Text] [Related]
2. New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria.
Andersson JA; Fitts EC; Kirtley ML; Ponnusamy D; Peniche AG; Dann SM; Motin VL; Chauhan S; Rosenzweig JA; Sha J; Chopra AK
Antimicrob Agents Chemother; 2016 Jun; 60(6):3717-29. PubMed ID: 27067323
[TBL] [Abstract][Full Text] [Related]
3. Plasmid-mediated doxycycline resistance in a Yersinia pestis strain isolated from a rat.
Cabanel N; Bouchier C; Rajerison M; Carniel E
Int J Antimicrob Agents; 2018 Feb; 51(2):249-254. PubMed ID: 29030266
[TBL] [Abstract][Full Text] [Related]
4. Reporter-Phage-Based Detection and Antibiotic Susceptibility Testing of
Moses S; Aftalion M; Mamroud E; Rotem S; Steinberger-Levy I
Microorganisms; 2021 Jun; 9(6):. PubMed ID: 34208306
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection.
Russell P; Eley SM; Green M; Stagg AJ; Taylor RR; Nelson M; Beedham RJ; Bell DL; Rogers D; Whittington D; Titball RW
J Antimicrob Chemother; 1998 Feb; 41(2):301-5. PubMed ID: 9533478
[TBL] [Abstract][Full Text] [Related]
6. [Yersinia pestis and plague - an update].
Stock I
Med Monatsschr Pharm; 2014 Dec; 37(12):441-8; quiz 449. PubMed ID: 25643450
[TBL] [Abstract][Full Text] [Related]
7. Yersinia pestis antibiotic resistance: a systematic review.
Lei C; Kumar S
Osong Public Health Res Perspect; 2022 Feb; 13(1):24-36. PubMed ID: 35255676
[TBL] [Abstract][Full Text] [Related]
8. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
[TBL] [Abstract][Full Text] [Related]
9. Inhalational Gentamicin Treatment Is Effective Against Pneumonic Plague in a Mouse Model.
Gur D; Glinert I; Aftalion M; Vagima Y; Levy Y; Rotem S; Zauberman A; Tidhar A; Tal A; Maoz S; Ber R; Pass A; Mamroud E
Front Microbiol; 2018; 9():741. PubMed ID: 29740404
[TBL] [Abstract][Full Text] [Related]
10. Oral vaccination against plague using Yersinia pseudotuberculosis.
Demeure CE; Derbise A; Carniel E
Chem Biol Interact; 2017 Apr; 267():89-95. PubMed ID: 27046452
[TBL] [Abstract][Full Text] [Related]
11. Early emergence of Yersinia pestis as a severe respiratory pathogen.
Zimbler DL; Schroeder JA; Eddy JL; Lathem WW
Nat Commun; 2015 Jun; 6():7487. PubMed ID: 26123398
[TBL] [Abstract][Full Text] [Related]
12. Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice.
Russell P; Eley SM; Bell DL; Manchee RJ; Titball RW
J Antimicrob Chemother; 1996 Apr; 37(4):769-74. PubMed ID: 8722542
[TBL] [Abstract][Full Text] [Related]
13. Activation of Heme Oxygenase Expression by Cobalt Protoporphyrin Treatment Prevents Pneumonic Plague Caused by Inhalation of
Willix JL; Stockton JL; Olson RM; Anderson PE; Anderson DM
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015027
[TBL] [Abstract][Full Text] [Related]
14. Treatment of plague: promising alternatives to antibiotics.
Anisimov AP; Amoako KK
J Med Microbiol; 2006 Nov; 55(Pt 11):1461-1475. PubMed ID: 17030904
[TBL] [Abstract][Full Text] [Related]
15.
Yang K; He Y; Park CG; Kang YS; Zhang P; Han Y; Cui Y; Bulgheresi S; Anisimov AP; Dentovskaya SV; Ying X; Jiang L; Ding H; Njiri OA; Zhang S; Zheng G; Xia L; Kan B; Wang X; Jing H; Yan M; Li W; Wang Y; Xiamu X; Chen G; Ma D; Bartra SS; Plano GV; Klena JD; Yang R; Skurnik M; Chen T
Front Immunol; 2019; 10():96. PubMed ID: 30915064
[No Abstract] [Full Text] [Related]
16. Origins of Yersinia pestis sensitivity to the arylomycin antibiotics and the inhibition of type I signal peptidase.
Steed DB; Liu J; Wasbrough E; Miller L; Halasohoris S; Miller J; Somerville B; Hershfield JR; Romesberg FE
Antimicrob Agents Chemother; 2015 Jul; 59(7):3887-98. PubMed ID: 25896690
[TBL] [Abstract][Full Text] [Related]
17. Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.
Lemaître N; Liang X; Najeeb J; Lee CJ; Titecat M; Leteurtre E; Simonet M; Toone EJ; Zhou P; Sebbane F
mBio; 2017 Jul; 8(4):. PubMed ID: 28743813
[TBL] [Abstract][Full Text] [Related]
18. Postexposure Administration of a Yersinia pestis Live Vaccine for Potentiation of Second-Line Antibiotic Treatment Against Pneumonic Plague.
Zauberman A; Gur D; Levy Y; Aftalion M; Vagima Y; Tidhar A; Chitlaru T; Mamroud E
J Infect Dis; 2019 Aug; 220(7):1147-1151. PubMed ID: 31095689
[TBL] [Abstract][Full Text] [Related]
19. Impact of Gentamicin Concentration and Exposure Time on Intracellular
VanCleave TT; Pulsifer AR; Connor MG; Warawa JM; Lawrenz MB
Front Cell Infect Microbiol; 2017; 7():505. PubMed ID: 29312891
[TBL] [Abstract][Full Text] [Related]
20. Antigenic profiling of yersinia pestis infection in the Wyoming coyote (Canis latrans).
Vernati G; Edwards WH; Rocke TE; Little SF; Andrews GP
J Wildl Dis; 2011 Jan; 47(1):21-9. PubMed ID: 21269993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
